What Is The Current and Historic Market Size Analysis Of The Visceral Pain Market?
The visceral pain market has seen considerable growth due to a variety of factors.
• The expansion of the visceral pain market has been significant in recent years. It is projected to increase from $13.84 billion in 2024 to $14.87 billion in 2025, with a compound annual growth rate (CAGR) of 7.5%.
Factors contributing to the growth during the historical period include an aging demographic, a rise in chronic illnesses, advancements in medical studies, the development of healthcare facilities, and increased awareness and diagnosis rates.
What Is The Forecast For The Visceral Pain Market Size?
The visceral pain market is expected to maintain its strong growth trajectory in upcoming years.
• The market for visceral pain is projected to witness substantial expansion in the coming years, reaching $18.71 billion in 2029 with a CAGR of 5.9%.
This anticipated growth during the forecast period can be ascribed to advancements in pain management technology, the rising preference for non-invasive treatments, the emergence of new markets and overlooked potentials, personalized medicine methodologies, and the incorporation of digital health solutions. The forecast period is also expected to see the trending shift towards multimodal pain management, an escalating focus on alternative therapies, the emergence of targeted treatments for specific pain types, an expanding role of telemedicine in pain management, and the integration of artificial intelligence into pain evaluation.
What Are The Essential Drivers Behind The Growth Of The Visceral Pain Market?
The growing need for painkillers is believed to be a key driver for the burgeoning visceral pain market. These painkillers, known as analgesics, work by reducing or inhibiting the sensation of pain in the brain, effectively managing visceral pain which originates from the internal organs by targeting the nervous system. Interestingly, by April 2024, it was reported by the UK's weekly medical journal, the New England Journal of Medicine that the number of clinicians prescribing buprenorphine had significantly increased to over 53,600, a jump of 11,500 from the previous year, December 2022. Consequently, this escalating demand for analgesics is significantly contributing to the expansion of the visceral pain market.
How Is The Global Visceral Pain Market Divided Into Key Segments?
The visceral pain market covered in this report is segmented –
1) By Drug Class: Calcium Channel Blockers, Nonsteroidal Anti-Inflammatory (NSAID), Other Drug Classes
2) By Indications: Interstitial Cystitis, Crohn’s, Irritable Bowel, Chronic Prostatitis, Other Indications
3) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines
2) By Nonsteroidal Anti-Inflammatory Drugs (NSAID): Selective COX-2 Inhibitors, Non-Selective NSAIDs
3) By Other Drug Classes: Opioids, Tricyclic Antidepressants (TCAs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
Pre-Book The Visceral Pain Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Visceral Pain Industry?
Leading firms in the visceral pain market are pursuing the development of novel products such as NHE3 Inhibitors, in a bid to deliver dependable services to their clientele. These inhibitors constitute a medicinal category that functions by restraining the Sodium-Proton-Exchanger subtype 3 (NHE3) in the gut. For example, Ardelyx, a pioneering biopharmaceutical establishment stationed in the United States, introduced an NHE3 Inhibitor medicine, IBSRELA, in April 2022. IBSRELA signifies a groundbreaking therapy for irritable bowel syndrome with constipation (IBS-C) adults, operating through the inhibition of Sodium-Hydrogen Exchanger 3 (NHE3) in both the small intestine and colon. Animal studies have demonstrated that it significantly reduces abdominal pain by mitigating visceral hypersensitivity and intestinal permeability.
Who Are the Key Players In The Visceral Pain Market?
Major companies operating in the visceral pain market report are:
• Walgreens Boots Alliance Inc.
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co.Inc.
• AbbVie Inc.
• Novartis AG
• Sanofi SA
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Bausch Health Companies Inc.
• Sun Pharmaceutical Industries Ltd.
• Perrigo Company PLC
• Dr. Reddy's Laboratories Ltd.
• Endo International PLC
• Grünenthal GmbH
• Glenmark Pharmaceuticals Limited
• Hisamitsu Pharmaceutical Co. Ltd.
• Chromocell Corporation
• Addex Therapeutics Ltd.
What Are The Regional Insights Into The Visceral Pain Market?
North America was the largest region in the visceral pain market in 2024. The regions covered in the visceral pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
